RxDoctor Payments Data

Agnes Bahng, MD

Internal Medicine · Reseda, CANPI 1740570100

Payments from drug & device makers

$1,079in general payments, 2019–2025

Across 55 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$645
  • Pfizer$73
  • Exact Sciences$69
  • Hologic Sales And Service, LLC$68
  • Gilead$52
  • AstraZeneca$31
  • plus $141 from 7 others

What the payments were for

  • Food & beverage$1,05498%
  • Education$252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,079 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$12,605
Medicare patients
44
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol50$55,961
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$26,138
JanuviaSitagliptin Phosphate23$24,610
JardianceEmpagliflozin12$19,880
KerendiaFinerenone12$19,341
OzempicSemaglutide12$15,463
Breo ElliptaFluticasone/Vilanterol11$9,065
Celecoxib17$3,628
Dexlansoprazole DrDexlansoprazole14$3,598
Rosuvastatin Calcium83$1,568
Albuterol Sulfate HfaAlbuterol Sulfate28$1,331
Atorvastatin Calcium159$1,178
Metoprolol Succinate62$1,004
Losartan Potassium100$993
Levothyroxine Sodium69$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$31$55,96150 claims
GSKTrelegy Ellipta, Breo Ellipta$23$35,20328 claims
MerckJanuvia$28$24,61023 claims
Boehringer IngelheimJardiance$16$19,88012 claims
Novo NordiskOzempic$25$15,46312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Reseda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →